Search
01/01/2023
Artificial intelligence: a new field of knowledge for nephrologists
De Arizón L.F., Viera E.R., Pilco M., Perera A., De Maeztu G., Nicolau A., Furlano M., Torra R.. Artificial intelligence: a new field of knowledge for nephrologists. Clinical Kidney Journal. 2023; 16(12)DOI:10.1093/ckj/sfad182. PMID:. IF:(Q/D).
01/01/2023
Glomerular diseases in pregnancy: pragmatic recommendations for clinical management
Fakhouri, F, Schwotzer, N, Cabiddu, G, Barratt, J, Legardeur, H, Garovic, V, Orozco-Guillen, A, Wetzels, J, Daugas, E, Moroni, G, Noris, M, Audard, V, Praga, M, Llurba, E, Wuerzner, G, Attini, R, Desseauve, D, Zakharova, E, Luders, C, Wiles, K, Leone, F, Jesudason, S, Costedoat-Chalumeau, N, Kattah, A, Soto-Abraham, V, Karras, A, Prakash, J, Lightstone, L, Ronco, P, Ponticelli, C, Appel, G, Remuzzi, G, Tsatsaris, V, Piccoli, GB. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. KIDNEY INTERNATIONAL. 2023; 103(2)DOI:10.1016/j.kint.2022.10.029. PMID:36481180. IF:14.800(Q1/1D).
01/01/2023
Results of a Systematic Intensive Follow-Up of 259 Cases of Obstetric Anal Sphincter Injury
Fons L.B., Roda O.P., Peró M., Roca P.F., González M.S.. Results of a Systematic Intensive Follow-Up of 259 Cases of Obstetric Anal Sphincter Injury. International Journal Of Childbirth. 2023; 13(3)DOI:10.1891/IJC-2022-0062. PMID:. IF:(Q/D).
01/01/2023
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Rodriguez-Vida, A, Maroto, P, Font, A, Martin, C, Mellado, B, Corbera, A, Orrillo, M, Reig, O, Querol, R, Rios-Hoyo, A, Cano, L, Alonso, J, Martinez, G, Galtes, S, Taus, A, Martinez-Garcia, M, Juanpere, N, Juan, O, Bellmunt, J. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. BRITISH JOURNAL OF CANCER. 2023; 128(1)DOI:10.1038/s41416-022-01991-4. PMID:36289372. IF:6.400(Q1/2D).
01/01/2023
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis
Labidi-Galy S.I., Rodrigues M., Sandoval J.L., Kurtz J.E., Heitz F., Mosconi A.M., Romero I., Denison U., Nagao S., Vergote I., Parma G., Nøttrup T.J., Rouleau E., Garnier G., El-Balat A., Zamagni C., Martín-Lorente C., Pujade-Lauraine E., Fiévet A., Ray-Coquard I.L.. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. ANNALS OF ONCOLOGY. 2023; 34(2)DOI:10.1016/j.annonc.2022.11.003. PMID:36564284. IF:56.700(Q1/1D).
01/01/2023
Comparison of laparoscopy and laparotomy in the management of early-stage ovarian cancer
Garcia N.G., Moreno C.S., Teixeira N., Lloret P.E., Guibourg R., Negre R.R.. Comparison of laparoscopy and laparotomy in the management of early-stage ovarian cancer. GYNECOLOGY AND MINIMALLY INVASIVE THERAPY-GMIT. 2023; 12(2)DOI:10.4103/gmit.gmit_99_22. PMID:37416098. IF:(Q/D).
01/01/2023
A Reappraisal of Lymphadenectomy in Common Gynecological Cancers
Habib N., Moufawad G., Hayek J., Futcher F., Chiantera V., Negre R.R., Devassy R., Centini G., Mereu L.. A Reappraisal of Lymphadenectomy in Common Gynecological Cancers. Clinical and Experimental Obstetrics & Gynecology. 2023; 50(9)DOI:10.31083/j.ceog5009181. PMID:. IF:0.400(Q4/9D).
01/01/2023
How have quality newspapers covered the microbiome? A content analysis of The New York Times, The Times, and El Pais
Prados-Bo, A, Casino, G. How have quality newspapers covered the microbiome? A content analysis of The New York Times, The Times, and El Pais. Journalism. 2023; 24(8)DOI:10.1177/14648849211067858. PMID:. IF:2.700(Q1/2D).